UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Cancer chemotherapy and pharmacology, 2018-09, Vol.82 (3), p.407-418

2018

Volltextzugriff (PDF)

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2698-2704

2010

Volltextzugriff (PDF)

Raf: A Strategic Target for Therapeutic Development Against Cancer

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6771-6790

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions

Cancer research (Chicago, Ill.), 2014-08, Vol.74 (16), p.4446-4457

2014

Volltextzugriff (PDF)

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2178-2185

2008

Volltextzugriff (PDF)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Frontiers in oncology, 2022-02, Vol.11, p.810023-810023

2022

Volltextzugriff (PDF)

Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4015-4015

2017

Volltextzugriff (PDF)

317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A343-A343

2020

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Clinical cancer research, 2007-05, Vol.13 (9), p.2675-2683

2007

Volltextzugriff (PDF)

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Clinical cancer research, 2015-10, Vol.21 (19), p.4286-4293

2015

Volltextzugriff (PDF)

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.946-953

2019

Volltextzugriff (PDF)

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

The lancet oncology, 2022-12, Vol.23 (12), p.1558-1570

2022

Volltextzugriff (PDF)

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Clinical cancer research, 2012-04, Vol.18 (8), p.2316-2325

2012

Volltextzugriff (PDF)

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-12, Vol.12 (24), p.7406-7413

2006

Volltextzugriff (PDF)

Barriers to Comprehensive Multidisciplinary Head and Neck Care in a Community Oncology Practice

American Society of Clinical Oncology educational book, 2021-03, Vol.41 (41), p.1-e245

2021

Volltextzugriff (PDF)

Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11532-11532

2023

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel

Clinical cancer research, 2007-06, Vol.13 (11), p.3293-3301

2007

Volltextzugriff (PDF)

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

The lancet. Gastroenterology & hepatology, 2019-09, Vol.4 (9), p.711-720

2019

Volltextzugriff (PDF)

A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

Cancer, 2012-12, Vol.118 (23), p.5733-5740

2012

Volltextzugriff (PDF)

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Clinical cancer research, 2016-03, Vol.22 (5), p.1095-1102

2016

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

Clinical cancer research, 2007-01, Vol.13 (2), p.532-539

2007

Volltextzugriff (PDF)

First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS1110-TPS1110

2020

Volltextzugriff (PDF)

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3064-3064

2020

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(88)

Sprache

Englisch
(88)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Raf: A Strategic Target for Therapeutic Development Against Cancer

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts

317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Barriers to Comprehensive Multidisciplinary Head and Neck Care in a Community Oncology Practice

Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma

Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody

Suchergebnisse filtern